This randomized clinical trials reports that among adults with mild COVID-19, a five-day course of ivermectin, compared with placebo, didn't significantly improve the time to resolution of symptoms. The findings don't support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.